Comparative Pharmacology
Head-to-head clinical analysis: FLUPHENAZINE HCL versus THORAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUPHENAZINE HCL versus THORAZINE.
FLUPHENAZINE HCL vs THORAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluphenazine is a phenothiazine antipsychotic that blocks postsynaptic D2 dopamine receptors in the mesolimbic system. It also exhibits alpha-adrenergic blocking, anticholinergic, and antihistaminergic effects.
Antagonist at dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histaminergic, and muscarinic receptors.
Oral: 2.5-10 mg/day in divided doses every 6-8 hours; maintenance: 1-5 mg/day. IM: 1.25-2.5 mg every 6-8 hours. Decanoate (long-acting): 12.5-25 mg IM every 2-4 weeks.
10-25 mg orally 3-4 times daily; maximum 800 mg/day. 25-50 mg intramuscularly every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is 15-30 hours (mean 24 hours) after IM administration; up to 9-12 hours after oral dosing due to first-pass metabolism. Steady-state reached in 5-10 days.
Terminal elimination half-life: 15–30 hours (mean ~24 h); may extend to 40+ h in elderly or hepatic impairment.
Primarily hepatic metabolism via CYP2D6; <1% excreted unchanged in urine. Biliary/fecal elimination accounts for ~20-30% of metabolites. Renal clearance is negligible.
Renal (biliary/fecal): ~70% renal as metabolites, ~30% biliary/fecal; <1% unchanged in urine.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic